Previous 10 | Next 10 |
Under Priority Review status, the FDA approves Alnylam Pharmaceuticals' ( ALNY +7.5% ) RNAi therapeutic givosiran, branded as Givlaari, for acute hepatic porphyria (AHP). More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Akcea Therapeutics, Inc., Healthcare st...
BOSTON and CARSLBAD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the closing of the exclusive licensing agreement with Pfizer Inc...
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
The following slide deck was published by Akcea Therapeutics, Inc. in conjunction with their 2019 Q3 earnings Read more ...
Image source: The Motley Fool. Akcea Therapeutics, Inc. (NASDAQ: AKCA) Q3 2019 Earnings Call Nov 5, 2019 , 4:30 p.m. ET Operator Continue reading
Akcea Therapeutics, Inc. (AKCA) Q3 2019 Earnings Conference Call November 5, 2019 4:30 p.m. ET Company Participants Kathleen Gallagher - VP of Corporate Communications and IR Damien McDevitt - Interim CEO Mike MacLean - CFO Kyle Jenne - Chief Commercial Officer Conference Ca...
Akcea Therapeutics (NASDAQ: AKCA ): Q3 GAAP EPS of -$0.34 beats by $0.19 . More news on: Akcea Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Reported Third Quarter 2019 Global Net Product Revenues of $12 Million WAYLIVRA ® (volanesorsen) launched in the E.U. Entered into a worldwide licensing agreement with Pfizer, Inc. for AKCEA-ANGPTL3-L Rx Conference Call Webcast Tuesday, November 5, 4:...
BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today recognizes Familial Chylomicronemia Syndrome (FCS) Awareness Day. FCS Awareness Day is a global observance held each year on the...
The $79 million that Vyndaqel contributed to Pfizer 's (NYSE: PFE) third-quarter revenue doesn't mean a whole lot to the pharmaceutical giant . It amounted to a whopping 0.6% of the company's overall revenue. But you can bet that executives at Alnylam Pharmaceuticals (NASDAQ: ALNY) , Ak...
News, Short Squeeze, Breakout and More Instantly...
Akcea Therapeutics Inc. Company Name:
AKCA Stock Symbol:
NASDAQ Market:
Akcea Therapeutics Inc. Website:
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif. , Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, In...
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif. , Oct. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...